Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 58, Issue 5, 2019, Pages 849-858

  Emery, Paul ^a   Rondon, Juan ^b   Parrino, Janie ^c   Lin, Yong ^d   Pena Rossi, Claudia ^d   Van Hoogstraten, Hubert ^d   Graham, Neil M H ^c   Liu, Nancy ^d   Paccaly, Anne ^c   Wu, Richard ^c   Spindler, Alberto ^e  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Arthritis and RheumaticDiseases of South Florida   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d SANOFI   (France)

^e UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Intravenous; RA; Sarilumab; Subcutaneous; Tocilizumab

Indexed keywords

AMINOTRANSFERASE; LIPID; SARILUMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; DEMOGRAPHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; OPEN STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THROMBOCYTE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; AGED; CLINICAL TRIAL; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85067699157     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key361     Document Type: Article

References (15)

1. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51:v311.
2. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010;2:24756.
3. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int 2014;2014:1.
4. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014;73:161625.
5. Weinblatt ME, Mease P, Mysler E et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/ active-controlled, dose-ranging study. Arthritis Rheumatol 2015;67:2591600.
6. Actemra (tocilizumab) injection for intravenous use injection, for subcutaneous use [package insert]. South San Francisco, CA, USA: Genentech, Inc., 2012.
7. Dörner T, Weinblatt M, Beneden KV et al. FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. Ann Rheum Dis 2017;76:575.
8. KEVZARA [package insert]. Bridgewater, NJ, USA: Sanofi-aventis US LLC, 2017.
9. Genovese MC, Fleischmann R, Kivitz AJ et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a Phase III study. Arthritis Rheum 2015;67:142437.
10. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:296880.
11. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:15808.
12. Hochberg MC, Chang RW, Dwosh I et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498502.
13. Summers C, Rankin SM, Condliffe AM et al. Neutrophil kinetics in health and disease. Trends Immunol 2010;31:31824.
14. Gibiansky L, Frey N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn 2012;39:516.
15. Kovalenko P, Paccaly A, Boyapati A, Xu C, Davis JD, DiCioccio AT. Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with RA after single-dose administration. Abstracts of the Annual Meeting of the Population Approach Group in Europe, PAGE 26, 2017, Abstr 7284. https://www.page-meeting.org/default.asp? abstract=7284 (26 November 2018, date last accessed).